<DOC>
	<DOCNO>NCT00021697</DOCNO>
	<brief_summary>The purpose study compare evaluate safety AVP-923 ( dextromethorphan/quinidine ) treatment emotional lability ALS patient .</brief_summary>
	<brief_title>Safety/Efficacy AVP-923 Treatment Emotional Lability ( Uncontrolled Crying &amp; Laughing ) Patients With ALS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<criteria>Inclusion : 18 80 year age , inclusive Confirmed diagnosis ALS probable ALS Clinical history pseudobulbar affect If female , must pregnant , breastfeed , plan pregnancy course study , must negative urine pregnancy test prior start study If female , must practice establish method birth control least prior month ( oral contraceptive tablet , hormonal implant device , intrauterine device , diaphragm contraceptive cream foam , condom spermicide , tubal ligation , abstinence ) surgically sterile postmenopausal Must willing take prohibit medication participation study Exclusion : Known sensitivity quinidine opiate drug ( codeine , etc . ) On antidepressive medication Recently ( within two month ) diagnose ALS Currently participate , within past 30 day participate , study another investigational new drug Previously receive treatment coadministration dextromethorphan quinidine History substance abuse within past two year Women pregnant likely become pregnant course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AVP-923</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>Quinidine</keyword>
	<keyword>Pseudobulbar Affect</keyword>
</DOC>